Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting

Volumn 35, Issue , 2016, Pages e450-e458

  Antonia, Scott J ^a   Vansteenkiste, Johan F ^a   Moon, Edmund ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN; TUMOR MARKER;

DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PATHOLOGY; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84980370219     PISSN: None     EISSN: 15488756     Source Type: Journal    
DOI: 10.14694/EDBK_158712     Document Type: Review

References (0)